logo
Plus   Neg
Share
Email

Fiserv Elects Frank Bisignano To Succeed Jeffery Yabuki As CEO

Fiserv Inc. (FISV), Thursday said its board has selected Frank Bisignano to succeed Jeffery Yabuki as Chief Executive Officer as of July 1.

Yabuki will step down following a 15-year career with the company. To ensure a seamless transition, Yabuki, Chairman of the Fiserv Board, will continue to serve as Executive Chairman for the remainder of 2020.

"With the successful integration of First Data well underway, this is the right time for Frank to lead the next phase of the company's evolution," said Yabuki.

Commenting on his appointment, Bisignano said, "It is an honor to assume the role as CEO of Fiserv; to serve clients with excellence, work with the talented team of leaders and associates and to continue the great track record of delivering differentiated value for our shareholders."

Bisignano has served as President, Chief Operating Officer and a Director of Fiserv since the company completed its acquisition of First Data in July 2019.

Meanwhile, Fiserv withdrew its financial guidance for 2020, due to the uncertainty surrounding the COVID-19 pandemic and the related negative impact on global economic activity.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
RELATED NEWS
Follow RTT